Does the 1:1:1 Transfusion Ratio Mortality Benefit Hold True in Ultra-massive Transfusion? A Study From the Product (Patient Related Outcomes During Ultra-massive transfusion multi-Center Trial) ConsortiumCourtney Meyer, Jonathan Nguyen, Melike Harfouche et al.|The American Surgeon|2025Cited by 4
Development of an Early Mortality Risk Prediction Model for Patients Receiving Ultra-Massive Blood Product Transfusion Based on Clinically Accessible Data from 11 U.S. Trauma CentersZachary Grady, Randi N. Smith, Jonathan Nguyen et al.|SSRN Electronic Journal|2025Cited by 0
Moderate- to High-grade Blunt Liver and Spleen Injuries Warrant Repeat Imaging to Identify Treatable ComplicationsLindsey L. Perea, Jamie Williams, Kelsey L. Fletcher et al.|Annals of Surgery|2025Cited by 0